Table 2. Serum antibody and co-expression status for MAGE antigens in ovarian cancer.

MAGE Antigen	A1	A3	A4	A10	C1	Any A
Autoantibody (ELISA)	10/285 (4%)	12/285 (4%)	7/115 (6%)	6/86 (7%)	10/93 (11%)	27/285 (9%)
Expression (rt-PCR or IHC)	42/281 (15%)	131/390 (36%)	186/399 (47%)	204/395 (52%)	42/267 (16%)	310/400 (78%)

A total of 400 patients were studied for MAGE expression. A subset of 285 patients were studied for anti-MAGE autoantibody. The numerator represents the number of antigen positive tumors or serology. The denominator represents the total number of successful assays for each antigen. Antigen specific numbers vary due to assay viability. Percentages represent the frequency of MAGE expression or MAGE-specific antibody.